Febuxostat Formyl Hydroxy Ethyl Ester CAS 161798-03-4 Purity >99.0% (HPLC) Febuxostat Intermediate Factory
Ruifu Chemical Supply Febuxostat Related Intermediates:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5
Chemical Name | Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate |
Synonyms | Febuxostat Formyl Hydroxy Ethyl Ester; Febuxostat Impurity 2; Febuxostat Intermediate 4 |
CAS Number | 161798-03-4 |
CAT Number | RF-PI1856 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C18H21NO4S |
Molecular Weight | 347.43 |
Density | 1.183 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | Light Yellow to Yellow Powder or Crystals |
Purity / Analysis Method | >99.0% (HPLC) |
Water Content (K.F) | <0.50% |
Residue on Ignition | <0.50% |
Total Impurities | <1.00% |
1 H NMR Spectrum | Consistent With Structure |
Test Standard | Enterprise Standard |
Usage | Intermediate of Febuxostat (CAS: 144060-53-7) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate (CAS: 161798-03-4) is an intermediate or impurity of Febuxostat (CAS: 144060-53-7). Febuxostat is a new generation xanthine oxidase inhibitor developed by Tejin Co. (Japan,) used clinically for for long-term treatment of hyperuicemia (gout,) a new and highly effective non-purine selective inhibitor of xanthine oxidase. It is not recommended for gout patients without hyperuricemia.